AA
KLRA

ALPS Advisors’s Kailera Therapeutics KLRA Stock Holding History

ALPS Advisors’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Buy
+131,000
New +$2.88M 0.01% 417

Other funds holding KLRA

ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HCA
Harbour Capital Advisors Tysons Corner, Virginia $549M AUM 54.99% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

ALPS Advisors's KLRA Position: Q2 2026 in Review

ALPS Advisors opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 131,000 shares worth $2.89M. The stake represents 0.01% of the portfolio and ranks #417 among its holdings.

17 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • ALPS Advisors held 131,000 shares of Kailera Therapeutics worth $2.89M as of Q2 2026.
  • Kailera Therapeutics was a new ALPS Advisors position in Q2 2026.
  • Kailera Therapeutics made up 0.01% of ALPS Advisors's portfolio in Q2 2026, its #417 holding.
  • 17 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.